RxDoctor Payments Data

William Deschner, MD

Gastroenterology · San Marcos, TXNPI 1023003563

Payments from drug & device makers

$9,365in general payments, 2019–2025

Across 549 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$786
  • Bristol Myers Squibb$638
  • Gilead$614
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$441
  • Pfizer$391
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$9,344100%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,365 in reported general payments places this provider in the 70th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$278,426
Medicare patients
707
Services billed
6,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase34$162,139
OcalivaObeticholic Acid11$101,428
Humira(Cf) PenAdalimumab14$94,162
XifaxanRifaximin13$37,996
ClenpiqSod Picosulf/Mag Ox/Citric Ac182$28,772
Mesalamine43$27,145
CreonLipase/Protease/Amylase12$26,971
LinzessLinaclotide31$26,829
Omeprazole514$7,986
Dexlansoprazole DrDexlansoprazole16$7,122
Budesonide DrBudesonide44$7,047
Ursodiol39$4,130
Pantoprazole Sodium213$2,557
Esomeprazole Magnesium23$1,385
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg46$1,321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$128$162,13934 claims
Intercept Pharmaceuticals, Inc.Ocaliva$184$101,42811 claims
AbbVieCreon, Linzess$3,003$53,79943 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$441$37,99613 claims
Ferring Pharmaceuticals Inc.Clenpiq$162$28,772182 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in San Marcos

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →